Bevacizumab biosimilar (Cipla BioTec)

贝伐珠单抗生物类似药 (Cipla BioTec)

Report date: 2022/08/29 20:00:24

Base Information

Drug NameBevacizumab biosimilar (Cipla BioTec)

Drug Alias Name贝伐人源化单抗生物仿制药 (Cipla BioTec)贝伐赛珠单抗生物仿制药 (Cipla BioTec)贝伐珠单抗生物仿制药 (Cipla BioTec)贝伐单抗生物仿制药 (Cipla BioTec)CBT-124

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNew Zealand

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

ATC CodeL01XC07